Monday, 1 March 2010

Phase II trial of LDN Results Released

From the MS Society Website:

Results of a phase II clinical trial testing the safety and effectiveness of low-dose naltrexone (LDN) as a symptom-relief treatment for people with MS have been published in the journal Annals of Neurology. The journal reported positive outcomes for mental quality of life, but no impact on physical quality of life in people with MS.